Press Releases

CRANBURY, N.J., Dec. 7, 2016 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE MKT: PTN) announced that it has closed on a previously disclosed underwritten public offering of units with gross proceeds of $16,500,000.  Canaccord Genuity acted as sole book-running manager, Roth Capital Partners acted as lead manager and Chardan Capital Markets acted as co-manager for the […]

Dec 01, 2016, 08:20 ET CRANBURY, N.J., Dec. 1, 2016 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE MKT: PTN) today announced the pricing of an underwritten public offering of 25,384,616 shares of its common stock and warrants to purchase 12,692,310 shares of its common stock for anticipated gross proceeds of $16.5 million, before deducting underwriting discounts

Nov 30, 2016, 04:36 ET CRANBURY, N.J., Nov. 30, 2016 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE MKT: PTN) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock and warrants to purchase shares of its common stock. There can be

Nov 15, 2016, 07:30 ET CRANBURY, N.J., Nov. 15, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2016.  Recent Highlights Bremelanotide – Under development

CRANBURY, N.J., Nov. 10, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2017 operating results on Tuesday, November 15, 2016  before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November

CRANBURY, N.J., Sept. 23, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that a review of the neurobiology and treatment efficacy of bremelanotide for hypoactive sexual desire disorder (“HSDD”) was presented at the

CRANBURY, N.J., Sept. 23, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that as previously disclosed in its Annual Report on Form 10-K for the year ended June 30, 2016, which was

CRANBURY, N.J., Sept. 20, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced financial results for its fourth quarter and fiscal year ended June 30, 2016.  Significant Highlights Bremelanotide – Under development

CRANBURY, N.J., Sept. 14, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter, fiscal year end 2016 operating results on Tuesday, September 20, 2016  before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September

CRANBURY, N.J., Aug. 8, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that Carl Spana, the Company’s President & Chief Executive Officer, will present at the 36th Annual Canaccord Genuity Growth Conference